RYTM PE Ratio & Valuation, Is RYTM Overvalued

Historical Valuation

Rhythm Pharmaceuticals Inc (RYTM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 27.10 is considered Overvalued compared with the five-year average of -12.69. The fair price of Rhythm Pharmaceuticals Inc (RYTM) is between 60.21 to 78.52 according to relative valuation method. Compared to the current price of 82.59 USD , Rhythm Pharmaceuticals Inc By Overvalued By 5.18%.

Relative Value

Fair Zone

60.21-78.52

Current Price：82.59

5.18%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Rhythm Pharmaceuticals Inc (RYTM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Rhythm Pharmaceuticals Inc (RYTM) has a current Price-to-Book (P/B) ratio of 47.05. Compared to its 3-year average P/B ratio of 37.78, the current P/B ratio is approximately 24.54% higher. Relative to its 5-year average P/B ratio of 23.12, the current P/B ratio is about 103.56% higher. Rhythm Pharmaceuticals Inc (RYTM) has a Forward Free Cash Flow (FCF) yield of approximately -1.56%. Compared to its 3-year average FCF yield of -6.00%, the current FCF yield is approximately -74.04% lower. Relative to its 5-year average FCF yield of -14.41%, the current FCF yield is about -89.20% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RYTM competitors is 11.93, providing a benchmark for relative valuation. Rhythm Pharmaceuticals Inc Corp (RYTM.O) exhibits a P/S ratio of 27.10, which is 127.09% above the industry average. Given its robust revenue growth of 36.87%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RYTM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RYTM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RYTM currently overvalued or undervalued?

Rhythm Pharmaceuticals Inc (RYTM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 27.10 is considered Overvalued compared with the five-year average of -12.69. The fair price of Rhythm Pharmaceuticals Inc (RYTM) is between 60.21 to 78.52 according to relative valuation method. Compared to the current price of 82.59 USD, Rhythm Pharmaceuticals Inc is Overvalued By 5.18%.

What is Rhythm Pharmaceuticals Inc (RYTM) fair value?

RYTM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Rhythm Pharmaceuticals Inc (RYTM) is between 60.21 to 78.52 according to relative valuation method.

How does RYTM's valuation metrics compare to the industry average?

The average P/S ratio for RYTM's competitors is 11.93, providing a benchmark for relative valuation. Rhythm Pharmaceuticals Inc Corp (RYTM) exhibits a P/S ratio of 27.10, which is 127.09% above the industry average. Given its robust revenue growth of 36.87%, this premium appears sustainable.

What is the current P/B ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Mar 25 2026?

As of Mar 25 2026, Rhythm Pharmaceuticals Inc (RYTM) has a P/B ratio of 47.05. This indicates that the market values RYTM at 47.05 times its book value.

What is the current FCF Yield for Rhythm Pharmaceuticals Inc (RYTM) as of Mar 25 2026?

As of Mar 25 2026, Rhythm Pharmaceuticals Inc (RYTM) has a FCF Yield of -1.56%. This means that for every dollar of Rhythm Pharmaceuticals Inc's market capitalization, the company generates -1.56 cents in free cash flow.

What is the current Forward P/E ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Mar 25 2026?

As of Mar 25 2026, Rhythm Pharmaceuticals Inc (RYTM) has a Forward P/E ratio of -34.25. This means the market is willing to pay $-34.25 for every dollar of Rhythm Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rhythm Pharmaceuticals Inc (RYTM) as of Mar 25 2026?

As of Mar 25 2026, Rhythm Pharmaceuticals Inc (RYTM) has a Forward P/S ratio of 27.10. This means the market is valuing RYTM at $27.10 for every dollar of expected revenue over the next 12 months.

RYTM Valuation